← Leaderboards
Christine A Iacobuzio-Donahue
Johns Hopkins University
$15,673,191
Attributed
$18,802,584
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$36,556,739 · 14
By mechanism
U2C$14,976,124 · 2
R35$6,879,131 · 1
P50$6,400,589 · 6
R01$4,336,240 · 3
U01$3,264,005 · 1
K08$700,650 · 1
Top collaborators
- Andrea Cercek5 shared
- William Robert Jarnagin5 shared
- Dana Pe'Er5 shared
- Nita Ahuja4 shared
- Hariharan Easwaran4 shared
- Eileen Mary O'Reilly3 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Gregory D Kirk$60,349,977
- Chloe L Thio$13,807,555
- Andrea L Cox$41,369,991
- Anna Mae Elizabeth Diehl$33,245,963
- Kathleen Schwarz$11,772,700
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsMalignant Neoplasm Of PancreasTumorSamplingCessation Of LifeExcisionTissuesOperative Surgical ProceduresNeoplasm MetastasisCancer EtiologyPancreasDiagnosisBaseUnited StatesProgramsCellsSiteCollaborationsAutopsyInstitutionResearch PersonnelResourcesMutationBiopsy
Grant awards (56)
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer$2,434,565
P50 · FY2025 · CA
Determining the mechanism of pks+ E.coli-associated carcinogenesis in early onset colorectal cancer.$176,000
P50 · FY2025 · CA
Administrative Core$167,346
P50 · FY2025 · CA · contact PI
Career Enhancement Program$82,969
P50 · FY2025 · CA · contact PI
The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer$2,281,895
P50 · FY2024 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability$985,909
R35 · FY2024 · CA · contact PI
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$623,923
U01 · FY2024 · CA
Administrative Core$138,209
P50 · FY2024 · CA · contact PI
Career Enhancement Program$70,796
P50 · FY2024 · CA · contact PI
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability$1,017,044
R35 · FY2023 · CA · contact PI
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$642,310
U01 · FY2023 · CA
Administrative Core$171,014
P50 · FY2023 · CA · contact PI
Career Enhancement Program$66,521
P50 · FY2023 · CA · contact PI
Transition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain Metastasis$2,576,383
U2C · FY2022 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability$1,017,043
R35 · FY2022 · CA · contact PI
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$649,386
U01 · FY2022 · CA
Biospecimen Acquisition, Processing and Classification Unit$351,703
U2C · FY2022 · CA · contact PI
Administrative Core$141,213
P50 · FY2022 · CA · contact PI
Career Enhancement Program$82,305
P50 · FY2022 · CA · contact PI
Transition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain Metastasis$2,111,318
U2C · FY2021 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability$895,633
R35 · FY2021 · CA · contact PI
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$665,665
U01 · FY2021 · CA
Biospecimen Acquisition, Processing and Classification Unit$227,351
U2C · FY2021 · CA · contact PI
Transition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain Metastasis$2,665,572
U2C · FY2020 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability$944,561
R35 · FY2020 · CA · contact PI
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)$682,721
U01 · FY2020 · CA
Biospecimen Acquisition, Processing and Classification Unit$337,605
U2C · FY2020 · CA · contact PI
Transition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain Metastasis$2,801,826
U2C · FY2019 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability$1,006,666
R35 · FY2019 · CA · contact PI
Biospecimen Acquisition, Processing and Classification Unit$531,549
U2C · FY2019 · CA · contact PI
Transition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain Metastasis$2,706,596
U2C · FY2018 · CA
Interrogating the Evolutionary Dynamics of Cancer for Clinical Benefit and Actionability$1,012,275
R35 · FY2018 · CA · contact PI
Biospecimen Acquisition, Processing and Classification Unit$666,221
U2C · FY2018 · CA · contact PI
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer$9,422
R01 · FY2017 · CA
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer$470,355
R01 · FY2016 · CA
(PQB6) Genetics of Subclonal Evolution in Pancreatic Cancer$282,056
R01 · FY2016 · CA · contact PI
Tissue Banks$110,007
P50 · FY2016 · CA · contact PI
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer$490,967
R01 · FY2015 · CA
(PQB6) Genetics of Subclonal Evolution in Pancreatic Cancer$282,056
R01 · FY2015 · CA · contact PI
Tissue Banks$118,439
P50 · FY2015 · CA · contact PI
(PQD3)Molecular Profiles associated with Long-Term Survival in pancreas Cancer$459,341
R01 · FY2014 · CA
(PQB6) Genetics of Subclonal Evolution in Pancreatic Cancer$354,825
R01 · FY2014 · CA · contact PI
Tissue Banks$117,478
P50 · FY2014 · CA · contact PI
(PQB6) Genetics of Subclonal Evolution in Pancreatic Cancer$336,150
R01 · FY2013 · CA · contact PI
TGF-beta Signaling in Pancreatic Cancer Progression$310,286
R01 · FY2013 · CA · contact PI
Tissue Banks$116,854
P50 · FY2013 · CA · contact PI
TGF-beta Signaling in Pancreatic Cancer Progression$330,091
R01 · FY2012 · CA · contact PI
Tissue Banks$124,978
P50 · FY2012 · CA · contact PI
TGF-beta Signaling in Pancreatic Cancer Progression$330,091
R01 · FY2011 · CA · contact PI
TGF-beta Signaling in Pancreatic Cancer Progression$340,300
R01 · FY2010 · CA · contact PI
TGF-beta Signaling in Pancreatic Cancer Progression$340,300
R01 · FY2009 · CA · contact PI
TARGETS OF METASTATIC PANCREATIC CANCER$140,130
K08 · FY2008 · CA · contact PI
TARGETS OF METASTATIC PANCREATIC CANCER$140,130
K08 · FY2007 · CA · contact PI
TARGETS OF METASTATIC PANCREATIC CANCER$140,130
K08 · FY2006 · CA · contact PI
TARGETS OF METASTATIC PANCREATIC CANCER$140,130
K08 · FY2005 · CA
TARGETS OF METASTATIC PANCREATIC CANCER$140,130
K08 · FY2004 · CA